Breyanzi
Payments companies reported to CMS as associated with Breyanzi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Breyanzi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Breyanzi
These are the largest totals companies reported as associated with Breyanzi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Marco Davila | Buffalo, NY | Medical Oncology | $104,961.94 |
| Konstantinos Sdrimas | Morgantown, WV | Hematology & Oncology | $69,360.51 |
| Paul Shaughnessy | San Antonio, TX | Hematology & Oncology | $59,970.62 |
| Akil Merchant | Los Angeles, CA | Hematology & Oncology | $58,281.16 |
| Abraham Kanate | Morgantown, WV | Hematology & Oncology | $44,758.11 |
| Elizabeth Brem | Orange, CA | Hematology & Oncology | $44,169.85 |
| Moshe Levy | Dallas, TX | Medical Oncology | $41,872.50 |
| Suzanne Fanning | Greenville, SC | Hematology & Oncology | $40,735.22 |
| Jeremy Pantin | Nashville, TN | Hematology & Oncology | $38,302.14 |
| Amitkumar Mehta | Birmingham, AL | Hematology & Oncology | $36,775.99 |
Prescribed Breyanzi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.